Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. KKR and Impilo will work together with Immedica’s management team to support Immedica’s continued growth, including the launch of the recently approved ultra-orphan drug Loargys, additional pipeline assets, and continued in-licensing and M&A. The company is also evaluating an expansion into the U.S. ahead of the regulatory filing and potential approval of Loargys by the U.S. FDA.
Read the full article: KKR and Impilo Announce Strategic Partnership Together with Management in Rare Disease Platform Immedica Pharma //
Source: https://www.businesswire.com/news/home/20240422283835/en/KKR-and-Impilo-Announce-Strategic-Partnership-Together-With-Management-in-Rare-Disease-Platform-Immedica-Pharma